Matthew H. G. Katz
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (11)
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Background/Purpose Risk‐stratified pancreatectomy clinical pathways using regional anesthesia and multimodality analgesia have decreased overall opioid use, but the additional benefits of robotic surgery in opioid reduction for pancreatoduodenectomy (PD) are unknown. We compared the inpatient opioid use between robotic PD and open PD. Methods Patients undergoing open PD within a protocol evaluating preincisional regional anesthetic block bundles were compared to consecutively‐treated patients undergoing robotic PD identified from a prospectively maintained single‐institutional database. Clinical characteristics, operative outcomes, pain scores and inpatient oral morphine equivalent (OME) use were compared between patients treated with robotic or open PD. Patients with a history of continuous‐release opioid dependence were excluded. Results Of 114 total patients, 25 underwent robotic PD and 89 underwent open PD. Intraoperative opioid use was not different ( P = .87), nor were cumulative pain scores. Robotic PD patients used significantly fewer OMEs per day on postoperative days 1–4 ( P = .039), used fewer total OMEs during hospitalization (robotic: median = 79, IQR 42.5–141; open: median = 126, IQR 61.3–203.8; P = .0036) and were discharged with fewer OMEs (robotic: median = 0, IQR 0–43.8; open: median = 25, IQR 0–75; P = .009) despite a shorter length of stay (robotic: median = 4, open: median = 5, P = .002). Conclusions Robotic PD patients required fewer inpatient OMEs than open PD while maintaining similar pain scores. A higher percentage of robotic PD patients tapered off of opioids prior to discharge than open surgery patients treated with a standardized opioid reduction protocol despite a shorter length of stay. These results provide a rationale for choosing robotic PD when feasible to minimize opioid use.
Year:
2022
Year:
2022
Collaborators (9)
Dan Zhao
Assistant professor
The University of Texas MD Anderson Cancer Center
Kuno Lehmann
University Hospital of Zurich
Eugene J. Koay
-
Russell Witt
Assistant Professor
University of Virginia
Naruhiko Ikoma
-
julien taieb
Professor Head of the department
Université Paris-Saclay
Deyali Chatterjee
Associate Professor
The University of Texas MD Anderson Cancer Center
Anirban Maitra
The University of Texas MD Anderson Cancer Center
An Ngo-Huang
Assistant Professor
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.